NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis $23.71 -0.04 (-0.16%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$23.67 -0.04 (-0.19%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Hims & Hers Health Stock (NYSE:HIMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hims & Hers Health alerts:Sign Up Key Stats Today's Range$23.30▼$24.5350-Day Range$18.73▼$31.0152-Week Range$13.74▼$70.43Volume14.75 million shsAverage Volume25.09 million shsMarket Capitalization$5.40 billionP/E RatioN/ADividend YieldN/APrice Target$28.90Consensus RatingHold Company Overview Hims & Hers Health, Inc. is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps. The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support. Through secure online questionnaires and video visits, patients receive personalized treatment plans covering conditions such as erectile dysfunction, acne, hair thinning, anxiety and depression. Hims & Hers also distributes supplements, vitamin formulations and topical solutions designed to complement its prescription offerings. Founded in 2017 by Andrew Dudum and headquartered in San Francisco, Hims & Hers emerged as one of the first telehealth subscriptions focused on consumer-friendly branding and straightforward access to care. In July 2021, the company completed a business combination with a special purpose acquisition company, enabling its public listing on the New York Stock Exchange under the ticker HIMS. Since its inception, Hims & Hers has pursued strategic partnerships and acquisitions to expand its medical and technological capabilities. Serving customers across the continental U.S., Hims & Hers continues to develop its digital care model by enhancing telehealth platform features, broadening its therapeutic categories and strengthening clinical support. Under the leadership of CEO Andrew Dudum and a team of healthcare and technology executives, the company aims to reduce barriers to medical access while driving scalable growth in the evolving virtual care market.AI Generated. May Contain Errors. Read More Hims & Hers Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreHIMS MarketRank™: Hims & Hers Health scored higher than 86% of companies evaluated by MarketBeat, and ranked 83rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on no strong buy ratings, 4 buy ratings, 11 hold ratings, and 2 sell ratings.Upside PotentialHims & Hers Health has a consensus price target of $28.90, representing about 21.9% upside from its current price of $23.71.Amount of Analyst CoverageHims & Hers Health has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth1,125.00% Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 1,125.00% in the coming year, from $0.04 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -263.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -263.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioHims & Hers Health has a PEG Ratio of 46.09. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 12.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted31.40% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently decreased by 9.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.33 News SentimentHims & Hers Health has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 37 news articles for Hims & Hers Health this week, compared to 12 articles on an average week.Search Interest173 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat Follows41 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,473,644.00 in company stock.Percentage Held by Insiders11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HIMS Stock News HeadlinesHims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by AnalystsMay 25 at 2:30 AM | americanbankingnews.comHims & Hers CEO is plotting new ways to upend traditional health careMay 24 at 9:37 AM | washingtonpost.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 25 at 1:00 AM | Brownstone Research (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)May 23 at 12:38 PM | theglobeandmail.comThe Silver Lining of Last Week's Hims & Hers Earnings MissHims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.May 21, 2026 | marketbeat.comHims & Hers Health (NYSE:HIMS) CFO Sells $187,938.00 in StockMay 20, 2026 | insidertrades.comHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.May 12, 2026 | marketbeat.comHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAs Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.May 8, 2026 | marketbeat.comSee More Headlines HIMS Stock Analysis - Frequently Asked Questions How have HIMS shares performed this year? Hims & Hers Health's stock was trading at $32.45 at the beginning of 2026. Since then, HIMS shares have decreased by 26.9% and is now trading at $23.7110. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.44. Hims & Hers Health's revenue was up 3.8% compared to the same quarter last year. Read the conference call transcript. Is Hims & Hers Health doing a stock buyback? Hims & Hers Health's Board of Directors approved a share repurchase program on Monday, November 17th 2025, which permits the company to buy back $250,000,000 in shares, according to EventVestor. This means that the company could purchase up to 3% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its stock is undervalued. Who are Hims & Hers Health's major shareholders? Top institutional shareholders of Hims & Hers Health include Bank of America Corp DE (1.91%), State of Michigan Retirement System (1.03%), Renaissance Technologies LLC (0.93%) and Bank of New York Mellon Corp (0.59%). Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Christiane Pendarvis, Irene Becklund, Irene Becklund, Deborah M Autor, Anja Manuel and Lynne Chou O'keefe. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hims & Hers Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/11/2026Today5/25/2026AGM 20266/11/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 HIMS's financial health is in the Green zone, according to TradeSmith. HIMS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MEDICAL INFO SYS Sub-IndustryHealthcare Current SymbolNYSE:HIMS CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees2,442Year Founded2017Price Target and Rating Average Price Target for Hims & Hers Health$28.90 High Price Target$60.00 Low Price Target$21.00 Potential Upside/Downside+21.9%Consensus RatingHold Rating Score (0-4)2.12 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E Ratio592.78 P/E Growth46.09Net Income$128.37 million Net Margins-0.56% Pretax Margin-1.61% Return on Equity6.10% Return on Assets1.52% Debt Debt-to-Equity Ratio2.18 Current Ratio1.69 Quick Ratio1.56 Sales & Book Value Annual Sales$2.35 billion Price / Sales2.30 Cash Flow$0.84 per share Price / Cash Flow28.38 Book Value$1.96 per share Price / Book12.10Miscellaneous Outstanding Shares227,940,000Free Float201,133,000Market Cap$5.40 billion OptionableOptionable Beta2.43 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NYSE:HIMS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
